Roche has signed a voluntary license agreement providing its popular influenza antiviral drug Xofluza for generic drugmakers to copy in 129 developing countries.

Two months after UCB revealed the success of Bimzelx in a head-to-head trial against AbbVie’s Skyrizi in patients with psoriatic arthritis, the Belgian drugmaker has unveiled the results. In the phase 3b study, 49% of those on Bimzelx achieved reduced disease activity versus 38% of those on Skyrizi at Week […]

With questions already swirling about the actual affordability impact of the government’s drug purchasing portal TrumpRx, the White House is updating the platform to address a key gap in the medicines it lists, albeit with a number of caveats remaining.

Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the Japanese drugmaker to pay $885 million in damages, a figure that could be roughly tripled under antitrust law.

A Novartis cross-border partnership is turning into a standoff. The Swiss pharma has unilaterally terminated a plant leasing contract with Chinese CDMO Porton Pharma Solutions after a regulatory hiccup.

Following a string of defeats for the industry in challenging the Inflation Reduction Act, Hail Mary efforts from a handful of companies to have their criticisms heard by the United States’ High Court have fallen flat.